EGFR Inhibitor WJ13404

Preferred Label : EGFR Inhibitor WJ13404;

NCIt definition : An orally bioavailable, fourth-generation epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR inhibitor WJ13404 targets, binds to, and inhibits the activity of EGFR, including wild-type EGFR and multiple EGFR resistance mutations, such as triple mutations Del19/T790M/C797S and L858R/T790M/C797S. This prevents EGFR-mediated signaling, which induces cell death and inhibits tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;

Molecule name : WJ 13404; WJ-13404;

NCI Metathesaurus CUI : CL1905841;

Details

Origin ID

C198691;

concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- EGFR Exon 19 Deletion Mutation [NCIt concept]
- EGFR NP_005219.2:p.C797S [NCIt concept]
- EGFR NP_005219.2:p.L858R [NCIt concept]
- EGFR NP_005219.2:p.T790M [NCIt concept]
- Epidermal Growth Factor Receptor [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients